Provided by Tiger Trade Technology Pte. Ltd.

Unicycive Therapeutics, Inc.

4.70
+0.14503.19%
Pre-market: 4.08-0.6150-13.10%05:59 EDT
Volume:862.71K
Turnover:4.05M
Market Cap:130.78M
PE:-3.01
High:4.81
Open:4.61
Low:4.57
Close:4.55
52wk High:8.74
52wk Low:3.93
Shares:27.86M
Float Shares:27.23M
Volume Ratio:0.89
T/O Rate:3.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5585
EPS(LYR):-1.6715
ROE:-101.07%
ROA:-40.59%
PB:2.46
PE(LYR):-2.81

Loading ...

Guggenheim Remains a Buy on Unicycive Therapeutics (UNCY)

TIPRANKS
·
Jul 01

Top Midday Decliners

MT Newswires Live
·
Jul 01

Unicycive Therapeutics is Maintained at Buy by B. Riley Securities

Dow Jones
·
Jul 01

Unicycive Therapeutics price target lowered to $15 from $22 at H.C. Wainwright

TIPRANKS
·
Jul 01

Unicycive Therapeutics CRL tied to same vendor deficiency, says B. Riley

TIPRANKS
·
Jun 30

Unicycive Shares Plunge After FDA Again Rejects Oxylanthanum Carbonate

Dow Jones
·
Jun 30

Top Premarket Decliners

MT Newswires Live
·
Jun 30

U.S. Stocks on the Move-aerovironment, Oklo

Reuters
·
Jun 30

Unicycive Therapeutics Shares Down 36.9% Premarket After US FDA Declines to Approve Co's Kidney Disease Drug

THOMSON REUTERS
·
Jun 30

Unicycive Therapeutics receives complete response letter from FDA for OLD NDA

TIPRANKS
·
Jun 30

US FDA Declines to Approve Unicycive's Drug for Dialysis Patients

Reuters
·
Jun 30

Unicycive Says FDA Issues CRL for OLC NDA over Third-party Manufacturing Deficiencies

Reuters
·
Jun 30

Unicycive Therapeutics - FDA Raises no Concerns on Clinical Efficacy or Safety Data, no Additional Data Requested

THOMSON REUTERS
·
Jun 30

Unicycive Therapeutics: Remain Confident in Efficacy & Safety of Olc; Optimistic That We Will be Able to Expeditiously Resubmit Nda

THOMSON REUTERS
·
Jun 30

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (olc) New Drug Application (nda)

THOMSON REUTERS
·
Jun 30

Unicycive Therapeutics - FDA Has not Conducted Inspection of Third-party Manufacturing Vendor for Resubmitted Nda

THOMSON REUTERS
·
Jun 30

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

GlobeNewswire
·
Jun 30

NASDAQ Trade Halt Halt News Pending at 07:00 Am

Reuters
·
Jun 30

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Unicycive Therapeutics (UNCY)

TIPRANKS
·
Jun 27

Unicycive Therapeutics shareholders ratified Grassi & Co. as auditor for fiscal 2026

Reuters
·
Jun 22